J
John G.F. Cleland
Researcher at National Institutes of Health
Publications - 1276
Citations - 125527
John G.F. Cleland is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 137, co-authored 1172 publications receiving 110227 citations. Previous affiliations of John G.F. Cleland include Northwestern University & Imperial College London.
Papers
More filters
Journal ArticleDOI
Precision Medicine for Cardiac Resynchronization: Predicting Quality of Life Benefits for Individual Patients-An Analysis From 5 Clinical Trials.
Michael E. Nassif,Yuanyuan Tang,John G.F. Cleland,William T. Abraham,Cecilia Linde,Michael R. Gold,James B. Young,J. Claude Daubert,Lou Sherfesee,Dan Schaber,Anthony Tang,Philip G. Jones,Suzanne V. Arnold,John A. Spertus +13 more
TL;DR: In this article, a multivariable model was proposed to predict changes in quality of life (QoL) with and without CRT, using patient-level data from 5 randomized trials comparing CRT with no CRT.
Journal ArticleDOI
Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure.
Koen W. Streng,Jozine M. ter Maaten,John G.F. Cleland,Christopher M. O'Connor,Beth A. Davison,Marco Metra,Michael M. Givertz,John R. Teerlink,Piotr Ponikowski,Daniel M. Bloomfield,Howard C. Dittrich,Hans L. Hillege,Dirk J. van Veldhuisen,Adriaan A. Voors,Peter van der Meer +14 more
TL;DR: The plasma concentrations of several biomarkers are either positively or negatively influenced by BMI, and these findings suggest that these markers should be interpreted with caution in patients with obesity.
Journal ArticleDOI
Bronchial hyperresponsiveness in heart failure.
Journal ArticleDOI
Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multicentre trial
Trond J. Cooper,John G.F. Cleland,Marco Guazzi,Pierpaolo Pellicori,Tuvia Ben Gal,Offer Amir,Abdallah Al-Mohammad,Andrew E. Clark,Alex McConnachie,Kjetil Steine,Kenneth Dickstein +10 more
TL;DR: The aim of this study was to determine the safety, tolerability, and efficacy of sildenafil in patients with HFrEF and indirect evidence of PHT.
Journal ArticleDOI
Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis.
Tobias Täger,Lutz Frankenstein,Dan Atar,Stefan Agewall,Norbert Frey,Morten Grundtvig,Andrew L. Clark,John G.F. Cleland,John G.F. Cleland,Hanna Fröhlich +9 more
TL;DR: In this article, the authors evaluated the comparative efficacy of individual SGLT2i and the influence of their respective receptor selectivity thereon using a network meta-analysis and showed that Sotagliflozin may be superior to highly selective SGLt2i in terms of renal outcomes.